-
Dec 17, 2024 | 
onclive.com | Mazyar Shadman
Sustained Superiority of Zanubrutinib vs Bendamustine + Rituximab in Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN CLL): 5-Year Follow-Up of Cohort 1 from the SEQUOIA Study Dr. Mazyar Shadman presents an OncLive Rapid Readout on the SEQUOIA study, highlighting 5-year follow-up data that confirm zanubrutinib’s sustained progression-free survival superiority over bendamustine plus rituximab in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma,...
-
Nov 7, 2024 | 
radcliffecardiology.com | Mazyar Shadman |Dan Lenihan |Joe Carver
Faculty: Overview Join Dr Mazyar Shadman(University of Washington, US), Dr Dan Lenihan (Saint Francis Healthcare System, US) and Dr Joe Carver (University of Pennsylvania, US) as they explore the latest advancements and challenges in managing cardiovascular manifestations in patients undergoing targeted therapies like Bruton's Tyrosine Kinase (BTK) inhibitors, Chimeric Antigen Receptor T-cell (CAR-T) therapies and cutting-edge immunotherapies.
-
Aug 28, 2024 | 
onclive.com | Mazyar Shadman
CommentaryVideoAugust 28, 2024Author(s):Mazyar Shadman, MD, MPH, discusses real-world outcomes following early dose adjustments of first-line ibrutinib in CLL/SLL.
-
Aug 14, 2024 | 
targetedonc.com | Mazyar Shadman
August 14, 2024By Focusing on the future of CLL/SLL treatment, Mazyar Shadman, MD, MPH, discusses promising therapies in the pipeline. Video content above is prompted by the following questions:What do you envision for the future of treatments in CLL/SLL? What emerging agents or combination regimens are in the pipeline that can further improve the treatment landscape in R/R CLL/SLL? Related Content Related Content
-
Aug 12, 2024 | 
onclive.com | Mazyar Shadman
CommentaryVideoAugust 12, 2024Author(s):Mazyar Shadman, MD, MPH, discusses the investigation of sonrotoclax in the CELESTIAL-TNCLL trial in treatment-naïve chronic lymphocytic leukemia.
-
Aug 7, 2024 | 
targetedonc.com | Mazyar Shadman
Perspectives on Indirect Comparisons of BTK Inhibitors for R/R CLL/SLLMazyar Shadman, MD, MPH, shares comprehensive insights on the latest analyses of zanubrutinib compared with other BTK inhibitors in relapsed/refractory CLL/SLL.
-
Aug 7, 2024 | 
targetedonc.com | Mazyar Shadman
Additional Data and Key Takeaways in CLL/SLL from EHA 2024Following EHA 2024, an expert on hematologic malignancies provides key takeaways and reviews additional data updates on treatments for CLL/SLL.
-
Jul 31, 2024 | 
targetedonc.com | Mazyar Shadman
July 31, 2024By An expert on CLL/SLL provides clinical insights on approaching the treatment of patients who progress beyond initial therapy. Video content above is prompted by the following questions:How do you approach treatment for patients that progress beyond initial therapy in CLL/SLL? What factors influence the choice of retreatment options after prior BTK inhibitor therapy? Related Content Related Content
-
Jul 31, 2024 | 
targetedonc.com | Mazyar Shadman
July 31, 2024By Mazyar Shadman, MD, MPH, discusses the safety profile of BTK inhibitors in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Video content above is prompted by the following questions:What safety concerns do you have for using BTK inhibitors in patients with CLL/SLL? What notable toxicities are demonstrated in the latest clinical data? How do you manage those toxicities in your practice? Related Content Related Content
-
Jul 24, 2024 | 
targetedonc.com | Mazyar Shadman
July 24, 2024By Following recent updates from the SEQUOIA Arm D and CAPTIVATE studies, Mazyar Shadman, MD, MPH, discusses the future implications of fixed-duration therapy for patients with CLL/SLL. Video content above is prompted by the following questions:What are the future implications of fixed-duration therapy for patients with CLL/SLL? What are the implications of the SEQUOIA Arm D and CAPTIVATE studies for this therapeutic approach? Related Content Related Content
